WO2003088981A1 - Methods of treating necrotizing enterocolitis - Google Patents
Methods of treating necrotizing enterocolitis Download PDFInfo
- Publication number
- WO2003088981A1 WO2003088981A1 PCT/US2003/011167 US0311167W WO03088981A1 WO 2003088981 A1 WO2003088981 A1 WO 2003088981A1 US 0311167 W US0311167 W US 0311167W WO 03088981 A1 WO03088981 A1 WO 03088981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- carbon monoxide
- gas
- necrotizing enterocolitis
- vessel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- This invention relates to the treatment of gastrointestinal disorders.
- CO Carbon monoxide
- Necrotizing enterocolitis is a disease of newborns characterized by gut barrier failure, intestinal necrosis, sepsis, and multi-system organ failure (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- the present invention is based, in part, on the discovery that administration of CO can protect against the development of NEC.
- the present invention features a method of treating, preventing, or reducing the risk of necrotizing enterocolitis in a patient.
- the method includes identifying a patient suffering from or at risk for necrotizing enterocolitis and administering to the patient a pharmaceutical composition comprising an amount of CO effective to treat necrotizing enterocolitis in the patient.
- the method can include the further step of monitoring the patient's NEC condition and/or determining whether the patient's condition has improved or the risk of NEC has abated.
- the pharmaceutical composition can be administered to the patient by any method known in the art for administering gases, liquids, and/or solids to patients, e.g., via inhalation, insufflation, infusion, injection, and/or ingestion.
- the pharmaceutical composition is administered to the patient by inhalation. In another embodiment, the pharmaceutical composition is administered to the patient orally. In still another embodiment, the pharmaceutical composition is administered directly to the abdominal cavity of the patient. In yet another embodiment, the pharmaceutical composition is administered by an extracorporeal membrane gas exchange device or an artificial lung.
- the patient can be an infant, e.g., a full-term infant, a premature infant and/or an infant that exhibits low birth weight.
- the infant can be a newborn, or can be, e.g., up to one year old (for example, up to six months, four months, three months, or two months old). The infant can be less than six weeks old, e.g., less than four weeks old.
- the NEC can be the result of any of a number of factors, e.g., hypoxia, hypothermia, hypotension, hyperviscosity of the blood, and/or acidosis, and/or where the patient has received an exchange transfusion, at least one hyperosmolar feed, a packed cell transfusion, and/or an overdosage of calcium antagonists. Further, the NEC can result from a situation where the patient suffers from mesenteric ischaemia and/or bacterial infection of the bowel wall (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- the NEC can result from surgery, e.g., where the patient has undergone, is about to undergo, or is undergoing surgery.
- the pharmaceutical composition can be in any form, e.g., gaseous or liquid form.
- the invention also features a method of treating or preventing necrotizing enterocolitis in a patient, which includes identifying a patient suffering from or at risk for necrotizing enterocolitis, providing a vessel containing a pressurized gas comprising CO gas, releasing the pressurized gas from the vessel to form an atmosphere comprising CO gas, and exposing the patient to the atmosphere, wherein the amount of CO in the atmosphere is sufficient to treat necrotizing enterocolitis in the patient.
- the invention features a method of performing abdominal surgery on a patient (e.g., an infant), which includes identifying a patient in need of abdominal surgery, wherein necrotizing enterocolitis is a significant risk of the abdominal surgery; performing abdominal surgery on the patient, and before, during, or after the performing step, causing the patient to inhale an amount of CO gas sufficient to reduce the risk of necrotizing enterocolitis in the patient.
- a patient e.g., an infant
- necrotizing enterocolitis is a significant risk of the abdominal surgery
- performing abdominal surgery on the patient and before, during, or after the performing step, causing the patient to inhale an amount of CO gas sufficient to reduce the risk of necrotizing enterocolitis in the patient.
- Also included in the invention is a method of treating necrotizing enterocolitis in a patient, which includes: (a) identifying a patient suffering from necrotizing enterocolitis; (b) performing surgery on the patient to resect an affected portion of the patient's bowel; and (c) administering to the patient a pharmaceutical composition comprising an amount of carbon monoxide effective to treat necrotizing enterocolitis in the patient after step (a) and before, during, or after step (b).
- the invention provides a vessel comprising medical grade compressed CO gas.
- the vessel can bear a label indicating that the gas can be used to treat NEC in a patient, e.g., an infant.
- the CO gas can be in an admixture with nitrogen gas, with nitric oxide and nitrogen gas, or with an oxygen-containing gas.
- the CO gas can be present in the admixture at a concentration of at least about 0.025%, e.g., at least about 0.05%, 0.10%, 0.50%, 1.0%, 2.0%, 10%, 50%, or 90%.
- the invention provides a method of treating NEC in a patient, which includes identifying a patient suffering from or at risk for NEC and administering to the patient at least one of the following treatments in conjunction with treatment with CO: inducing HO-1 or ferritin in the patient; expressing recombinant HO-1 or ferritin in the patient; and administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, or apoferritin, iron, desferoxamine, or iron dextran to the patient.
- a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, or apoferritin, iron, desferoxamine, or iron dextran to the patient.
- CO also contemplated is use of CO and any of the above-listed agents in the preparation of a medicament for treatment or prevention of NEC.
- the invention provides a method of treating NEC in a patient, which includes identifying a patient suffering from or at risk for NEC and administering at least one of the following treatments in conjunction with treatment with CO: intravenous nutrition; intravenous hydration; antimicrobial agents; performing nasogastric decompression on the patient, performing surgery on the patient; and draining the patient's peritoneal cavity.
- CO in the manufacture of a medicament for treatment or prevention of NEC.
- the medicament can be used in a method for treating NEC in a patient suffering from or at risk for NEC in accordance with the methods described herein.
- the medicament can be in any form described herein, e.g., a liquid or gaseous CO composition.
- NEC intermittent hypoxia and formula feeding
- Fig. 2A is a photomicrograph (40X magnification) of a hematoxylin and eosin- stained ileal whole mount illustrating the effect of breast feeding on a neonatal rat. The sample was obtained on day four.
- Fig. 2B is a photomicrograph (40X magnification) of a hematoxylin and eosin- stained ileal whole mount illustrating the effect of breast feeding and CO exposure on a neonatal rat. The sample was obtained on day four.
- Fig. 2C is a photomicrograph (40X magnification) of a hematoxylin and eosin- stained ileal whole mount illustrating the effect of formula feeding plus hypoxia exposure on a neonatal rat. The sample was obtained on day four. Architectural changes including villous atrophy and cellular vacuolization can be observed.
- Fig. 2D is a photomicrograph (40X magnification) of a hematoxylin and eosin- stained ileal whole mount illustrating the effect of formula feeding, plus hypoxia exposure and CO exposure on a neonatal rat. Fewer architectural changes occur as compared to the sample shown in Fig. 2C. The sample was obtained on day four.
- Fig. 2C is a photomicrograph (40X magnification) of a hematoxylin and eosin- stained ileal whole mount illustrating the effect of formula feeding, plus hypoxia exposure and CO exposure on a neonatal rat. Fewer architectural changes occur as
- FIG. 3 A is a photomicrograph (60X magnification) of a terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL)-stained ileal whole mount illustrating the effect of breast feeding on a neonatal rat. The sample was obtained on day four.
- TUNEL terminal deoxynucleotidyl transferase mediated dUTP nick end labeling
- Fig. 3B is a photomicrograph (60X magnification) of a TUNEL-stained ileal whole mount illustrating the effect of breast feeding and CO exposure on a neonatal rat. The sample was obtained on day four.
- Fig. 3C is a photomicrograph (60X magnification) of a TUNEL-stained ileal whole mount illustrating the effect of formula feeding plus hypoxia exposure on a neonatal rat. The sample was obtained on day four. Ileum from hypoxia/formula-fed treated rats exhibits increased TUNEL staining compared to that from breast fed animals.
- Fig. 3D is a photomicrograph (60X magnification) of a TUNEL-stained ileal whole mount illustrating the effect of formula feeding plus hypoxia exposure, and CO exposure on a neonatal rat. The sample was obtained on day four. A decrease in TUNEL positive cells can be observed.
- Fig. 5 is a picture of a Western blot illustrating that CO treatment decreases ileal expression of COX-2 and LL-l ⁇ in hypoxia-exposed and formula-fed neonatal rats, as compared to controls.
- the presence (+) or absence (-) of each treatment (breast feeding (BF), formula-feeding plus hypoxia exposure (FF/Hypoxia) and CO exposure (CO)) is indicated beneath each lane of the Western blot.
- Blot demonstrates 3-4 animals per group and is representative of all animals in the study.
- Fig. 6 is a picture of a Western blot illustrating that exposure to CO abrogates experimental NEC-induced ileal iNOS expression and protein nitration in neonatal rats. 5 The presence (+) or absence (-) of each treatment (breast feeding (BF), formula-feeding plus hypoxia exposure (FF/Hypoxia) and CO exposure (CO) is indicated beneath each lane of the Western blot.
- BF breast feeding
- FF/Hypoxia formula-feeding plus hypoxia exposure
- CO CO
- Fig. 7 is a bar graph illustrating that CO exposure and induction of HO-1 decreases TNF- /Actinomycin D (TNF/ActD)-induced IEC-6 cell death.
- Viability of o TNF- ⁇ (TNF; 10ng/ml)/Actinomycin D (ActD; 200ng/ml)-treated LEC-6 cells was assayed after 18 hours by measuring cellular ATP content.
- CO treatment (CO; gray bars; 250 ppm) was initiated 1 hour prior to administration of TNF- ⁇ / ActD and maintained throughout the duration of the experiment.
- Fig. 8 A is a picture of a Western blot illustrating (at 24 hours) that iNOS protein expression is inhibited in lipopolysaccharide (LPS) and/or hypoxia (1% oxygen) treated 0 LEC-6 cells. CO treatment (250ppm) was initiated lhour before the addition of
- LPS lipopolysaccharide
- hypoxia 1% oxygen
- LPS/hypoxia LPS/hypoxia and maintained throughout the experiment.
- the combination of LPS (10 or 100 ng/ml) plus hypoxia increased iNOS protein expression, an effect that was inhibited by CO.
- the presence (+) or absence (-) of each treatment lipopolysaccharide (lps), hypoxia exposure (hypoxia) and CO exposure (CO)) is indicated beneath each 5 lane of the Western blot.
- Fig. 8B is a bar graph illustrating that rat iNOS promoter activity in LPS (100 ng/ml)/hypoxia (1% oxygen; lps/hypoxia)-treated IEC-6 cells is limited by exposure to CO. Cells were assayed for luciferase activity. The combination of LPS plus hypoxia resulted in a 4.9 ⁇ 0.3 fold increase in transcriptional activation of the 0 iNOS promoter (P ⁇ 0.05). CO limited this transcriptional activation to a 1.7 ⁇ 0.2 fold increase (P ⁇ 0.05). Results are mean ⁇ standard error of 3 independent studies performed in triplicate. Fig.
- 8C is a picture of a Western blot illustrating that cytokine-induced iNOS protein expression is inhibited in IEC-6 cells by induction of HO-1 or treatment with CO.
- IEC-6 cells were treated with a cytokine mixture (CM) containing TNF- ⁇ (lOng/ml), LL-l ⁇ (500 U/ml), and IFN- ⁇ (1000 U/ml) for 24 hours.
- CM cytokine mixture
- CM cytokine mixture
- CO CO
- CoPP cobalt o protoporphyrin
- 8D is a bar graph illustrating that the nitrite levels in supernatantants of TEC-6 cells that are exposed to CM and either CO or CoPP are lower than those of IEC- 6 cells exposed to CM and air (as determined by Griess assay).
- Cytokine stimulation increased nitrite to 17.2+0.9 ⁇ M compared to 1.4 ⁇ 0.3 ⁇ M in unstimulated controls 5 (P ⁇ 0.01).
- CO and CoPP significantly inhibited this cytokine effect resulting in nitrite levels of 9.8 ⁇ 0.7 and 10.4 + 1.0, respectively (P ⁇ 0.05 compared to CM-stimulated cells).
- carbon monoxide (or “CO") as used herein describes molecular CO in its gaseous state, compressed into liquid form, or dissolved in aqueous solution.
- carbon monoxide composition and “pharmaceutical composition comprising carbon monoxide” is used throughout the specification to describe a gaseous or liquid 5 composition containing CO that can be administered to a patient and/or an organ, e.g., an organ affected by NEC.
- an organ e.g., an organ affected by NEC.
- the skilled practitioner will recognize which form of the pharmaceutical composition, e.g., gaseous, liquid, or both gaseous and liquid forms, is preferred for a given application.
- effective amount and “effective to treat,” as used herein, refer to 0 an amount or concentration of CO utilized for period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome in a patient.
- Effective amounts of CO for use in the present invention include, for example, amounts that reduce the symptoms of NEC in a patient, or improve the outcome.
- effective amounts of CO generally fall within the range of about 0.0000001%? to about 0.3% by weight, e.g., 0.0001% to about 0.25% by weight, preferably at least about 0.001%, e.g., at least 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight of CO.
- effective amounts generally fall within the range of about 0.0001 to about 0.0044 g CO/100 g liquid, e.g., at least 0.0001, 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, or 0.0042 g CO/100 g aqueous solution.
- Preferred ranges include, e.g., about 0.0010 to about 0.0030 g CO/100 g liquid, about 0.0015 to about 0.0026 g CO/100 g liquid, or about 0.0018 to about 0.0024 g CO/100 g liquid.
- amounts outside of these ranges may be used, depending upon the application.
- the term "patient" is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods of the present invention is provided. Veterinary applications are clearly contemplated by the present invention.
- the term includes but is not limited to mammals, e.g., humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats.
- the term "treat(ment),” is used herein to describe delaying the onset of, inhibiting, or alleviating the effects of a condition, e.g., NEC, in a patient.
- NEC neurotizing enterocolitis
- bowel e.g., the lower portion of the small intestine (ileum), the colon, and/or the upper small intestine.
- necrotizing enterocolitis is associated with many factors, e.g., low birth weight, hypoxia, hypothermia, hypotension, hyperviscosity, acidosis, or the presence of free oxygen radicals (Id.).
- Other risk factors include umbilical artery cannulae, exchange transfusion, hyperosmolar feeds, packed cell transfusion, or overdosage with calcium antagonists (Id.).
- Such factors may cause mesenteric ischaemia, which may allow bacterial infection of the bowel wall, resulting in necrosis of the infected tissue and/or perforation of the bowel wall and septicemia (Id.).
- NEC can also occur in newborns following surgery for gastrointestinal or other conditions (Id.).
- a patient can be diagnosed as suffering from NEC by any method known in the art, e.g., by a physician's diagnosis (e.g., using imaging techniques such as ultrasonography, x-ray, and/or blood tests).
- a physician's diagnosis e.g., using imaging techniques such as ultrasonography, x-ray, and/or blood tests.
- Individuals considered at risk for developing NEC may benefit particularly from the invention, primarily because prophylactic treatment can begin before there is any evidence of NEC.
- Individuals "at risk” include, e.g., premature and newborn infants, or individuals suffering from any of the conditions or having the risk factors described above. Skilled practitioners will appreciate that a patient can be diagnosed as being at risk for NEC by any method known in the art, e.g., by a physician's diagnosis (e.g., by a physician's assessment of a patient's risk factors).
- a CO composition may be a gaseous CO composition.
- Compressed or pressurized gas useful in the methods of the invention can be obtained from any commercial source, and in any type of vessel appropriate for storing compressed gas.
- compressed or pressurized gases can be obtained from any source that supplies compressed gases, such as oxygen, for medical use.
- the term "medical grade" gas, as used herein, refers to gas suitable for administration to patients as defined herein.
- the pressurized gas including CO used in the methods of the present invention can be provided such that all gases of the desired final composition (e.g., CO, He, NO, CO 2 , O 2 , N 2 ) are in the same vessel, except that NO and O 2 cannot be stored together.
- the methods of the present invention can be performed using multiple vessels containing individual gases.
- a single vessel can be provided that contains CO, with or without other gases, the contents of which can be optionally mixed with room air or with the contents of other vessels, e.g., vessels containing oxygen, nitrogen, carbon dioxide, compressed air, or any other suitable gas or mixtures thereof.
- Gaseous compositions administered to a patient according to the present invention typically contain 0% to about 79% by weight nitrogen, about 21% to about 100% by weight oxygen and about 0.0000001 % to about 0.3% by weight (corresponding to about 1 ppb or 0.001 ppm to about 3,000 ppm) CO.
- the amount of nitrogen in the gaseous composition is about 79% by weight
- the amount of oxygen is about 21% by weight
- the amount of CO is about 0.0001% to about 0.25% by weight.
- the amount of CO is preferably at least about 0.001%, e.g., at least
- gaseous CO compositions having concentrations of CO greater than 0.3% may be used for short periods (e.g., one or a few breaths), depending upon the application.
- a gaseous CO composition may be used to create an atmosphere that comprises CO gas.
- An atmosphere that includes appropriate levels of CO gas can be created, for example, by providing a vessel containing a pressurized gas comprising CO gas, and 5 releasing the pressurized gas from the vessel into a chamber or space to form an atmosphere that includes the CO gas inside the chamber or space.
- the gases can be released into an apparatus that culminates in a breathing mask or breathing tube, thereby creating an atmosphere comprising CO gas in the breathing mask or breathing tube, ensuring the patient is the only person in the room exposed to 0 significant levels of CO.
- CO levels in an atmosphere can be measured or monitored using any method known in the art. Such methods include electrochemical detection, gas chromatography, radioisotope counting, infrared absorption, colorimetry, and electrochemical methods based on selective membranes (see, e.g., Sunderman et al., 5 Clin. Chem. 28:2026-2032, 1982; Ingi et al, Neuron 16:835-842, 1996). Sub-parts per million CO levels can be detected by, e.g., gas chromatography and radioisotope counting.
- a CO composition may also be a liquid CO composition.
- a liquid can be made into a CO composition by any method known in the art for causing gases to become dissolved in liquids.
- the liquid can be placed in a so-called "CO 2 incubator” and exposed to a continuous flow of CO, preferably balanced with carbon dioxide, until a desired concentration of CO is reached in the liquid.
- CO gas can be "bubbled” directly into the liquid until the desired concentration of CO in the liquid is reached. The amount of CO that can be dissolved in a given aqueous solution increases with decreasing temperature.
- an appropriate liquid may be passed through tubing that allows gas diffusion, where the tubing runs through an atmosphere comprising CO (e.g., utilizing a device such as an extracorporeal membrane oxygenator).
- the CO diffuses into the liquid to create a liquid CO composition.
- liquid composition intended to be introduced into a living animal will be at or about 37°C at the time it is introduced into the animal.
- the liquid can be any liquid known to those of skill in the art to be suitable for administration to patients (see, for example, Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- the liquid will be an aqueous solution.
- solutions include Phosphate Buffered Saline (PBS), CelsiorTM, PerfadexTM, Collins solution, citrate solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- the liquid is Ringer's Solution, e.g., lactated Ringer's Solution, or any other liquid that can be used infused into a patient.
- the liquid includes blood, e.g., whole blood.
- Any suitable liquid can be saturated to a set concentration of CO via gas diffusers.
- pre-made solutions that have been quality controlled to contain set levels of CO can be used. Accurate control of dose can be achieved via measurements with a gas permeable, liquid impermeable membrane connected to a CO analyzer. Solutions can be saturated to desired effective concentrations and maintained at these levels. Treatment of Patients with Carbon Monoxide Compositions
- a patient can be treated with a CO composition by any method known in the art of administering gases and/or liquids to patients.
- CO compositions can be administered to a patient diagnosed with, or determined to be at risk for, NEC, e.g., newborns or premature infants.
- the present invention contemplates the systemic administration of liquid or gaseous CO compositions to patients (e.g., by inhalation and/or ingestion), and the topical administration of the compositions to the patient's gastrointestinal tract (e.g., by ingestion, insufflation, and/or introduction into the abdominal cavity).
- Gaseous CO compositions can be delivered systemically to a patient, e.g., a patient diagnosed with, or determined to be at risk for NEC. Gaseous CO compositions are typically administered by inhalation through the mouth or nasal passages to the lungs, where the CO is readily absorbed into the patient's bloodstream.
- concentration of active compound (CO) utilized in the therapeutic gaseous composition will depend on absorption, distribution, inactivation, and excretion (generally, through respiration) rates of the CO as well as other factors known to those of skill in the art.
- Medical grade CO (concentrations can vary) can be purchased mixed with air or another oxygen-containing gas in a standard tank of compressed gas (e.g., 21% O 2 , 79% N 2 ). It is non-reactive, and the concentrations that are required for the methods of the present invention are well below the combustible range (10% in air). In a hospital setting, the gas presumably will be delivered to the bedside where it will be mixed with oxygen or house air in a blender to a desired concentration in ppm (parts per million). The patient will inhale the gas mixture through a ventilator, which will be set to a flow rate based on patient comfort and needs. This is determined by pulmonary graphics (i.e., respiratory rate, tidal volumes etc.).
- Fail-safe mechanism(s) to prevent the patient from unnecessarily receiving greater than desired amounts of CO can be designed into the delivery system.
- the patient's CO level can be monitored by studying (1) carboxyhemoglobin (COHb), which can be measured in venous blood, and (2) exhaled CO collected from a side port of the ventilator. CO exposure can be adjusted based upon the patient's health status and on the basis of the markers. If necessary, CO can be washed out of the patient by switching to 100% O 2 inhalation. CO is not metabolized; thus, whatever is inhaled will ultimately be exhaled except for a very small percentage that is converted to CO 2 . CO can also be mixed with any level of O 2 to provide therapeutic delivery of CO without consequential hypoxic conditions.
- a CO-containing gas mixture is prepared as above to allow passive inhalation by the patient using a facemask or tent.
- the concentration inhaled can be changed and can be washed out by simply switching over to 100% O 2 .
- Monitoring of CO levels would occur at or near the mask or tent with a fail-safe mechanism that would prevent too high of a concentration of CO from being inhaled.
- Portable inhaler Compressed CO can be packaged into a portable inhaler device and inhaled in a metered dose, for example, to permit intermittent treatment of a recipient who is not in a hospital setting.
- Different concentrations of CO could be packaged in the containers.
- the device could be as simple as a small tank (e.g., under 5 kg) of appropriately diluted CO with an on-off valve and a tube from which the patient takes a whiff of CO according to a standard regimen or as needed.
- An artificial lung designed for O 2 delivery and CO 2 removal can be used for CO delivery.
- the catheter when implanted, resides in one of the large veins and would be able to deliver CO at given concentrations either for systemic delivery or at a local site.
- the delivery can be a local delivery of a high concentration of CO for a short period of time at the site of the procedure, e.g., in proximity to the small intestine (this high concentration would rapidly be diluted out in the bloodstream), or a relatively longer exposure to a lower concentration of CO (see, e.g., Hattler et al, Artif. Organs 18(11):806-812 (1994); and Golob et al, ASAIO J., 47(5):432-437 (2001)).
- the patient would be inside an airtight chamber that would be flooded with CO (at a level that does not endanger the patient, or at a level that poses an acceptable risk without the risk of bystanders being exposed.
- the chamber could be flushed with air (e.g., 21% O 2 , 79% N 2 ) and samples could be analyzed by CO analyzers to ensure no CO remains before allowing the patient to exit the exposure system.
- liquid CO compositions can be created for systemic delivery to a patient, e.g., by infusion into a patient.
- liquid CO compositions such as CO-saturated Ringer's Solution
- CO-partially or completely saturated whole (or partial) blood can be infused into the patient.
- agents capable of delivering doses of CO gas or liquid can be utilized (e.g., CO releasing gums, creams, ointments or patches).
- CO compositions can be applied directly to the gastrointestinal tract, e.g., to the interior and/or exterior of the entire gastrointestinal tract, or to any portion thereof.
- a gaseous composition can be directly applied to the gastrointestinal tract of a patient, e.g., a premature infant or newborn, by any method known in the art for insufflating gases into a patient.
- gases e.g., carbon dioxide
- gases are often insufflated into the gastrointestinal tract and the abdominal cavity of patients to facilitate examination during endoscopic and laproscopic procedures, respectively (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- Aqueous CO compositions can also be administered topically to the gastrointestinal tract of a patient.
- Aqueous forms of the compositions can be administered by any method known in the art for administering liquids to patients.
- aqueous compositions can be applied directly to the interior and/or exterior of the gastrointestinal tract.
- the aqueous form can be administered orally, e.g., by causing the patient to ingest an encapsulated or unencapsulated dose of the aqueous CO composition.
- liquids e.g., saline solutions containing dissolved CO, can be injected into the gastrointestinal tract and the abdominal cavity of patients during endoscopic and laproscopic procedures, respectively.
- an in situ exposure can be carried out by flushing the gastrointestinal tract or a portion thereof with a liquid CO composition (see Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press (1994)).
- HO-1 hemeoxygenase-1
- induction or expression of hemeoxygenase-1 in conjunction with administration of CO.
- HO-1 can be induced in a patient suffering from or at risk for NEC.
- induce(d) means to cause increased production of a protein, e.g., HO-1, in isolated cells or the cells of a tissue, organ or animal using the cells' own endogenous (e.g., non-recombinant) gene that encodes the protein.
- HO-1 can be induced in a patient by any method known in the art.
- production of HO-1 can be induced by hemin, by iron protoporphyrin, or by cobalt protoporphyrin.
- non-heme agents including heavy metals, cytokines, hormones, NO, COCl 2 , endotoxin and heat shock are also strong inducers of HO-1 expression (Choi et al, Am. J. Respir. Cell Mol. Biol. 15:9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Tenhunen et al, J. Lab. Clin. Med. 75:410-421, 1970).
- HO-1 is also highly induced by a variety of agents causing oxidative stress, including hydrogen peroxide, glutathione depletors, UV irradiation, endotoxin and hyperoxia (Choi et al, Am. J. Respir. Cell Mol. Biol. 15:9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Keyse et al, Proc. Natl. Acad. Sci. USA 86:99-103, 1989).
- a "pharmaceutical composition comprising an inducer of HO-1” means a pharmaceutical composition containing any agent capable of inducing HO-1 in a patient, e.g., any of the agents described above, e.g., hemin, iron protoporphyrin, and/or cobalt protoporphyrin.
- HO-1 expression in a cell can be increased via gene transfer.
- the term "express(ed)” means to cause increased production of a protein, e.g., HO-1 or ferritin, in isolated cells or the cells of a tissue, organ or animal using an exogenously administered gene (e.g., a recombinant gene).
- the HO-1 or ferritin is preferably of the same species (e.g., human, mouse, rat, etc.) as the recipient, in order to minimize any immune reaction.
- Expression could be driven by a constitutive promoter (e.g., cytomegalovirus promoters) or a tissue-specific promoter (e.g., milk whey promoter for mammary cells or albumin promoter for liver cells).
- An appropriate gene therapy vector e.g., retrovirus, adenovirus, adeno associated virus (AAV), pox (e.g., vaccinia) virus, human immunodeficiency virus (HIV), the minute virus of mice, hepatitis B virus, influenza virus, Herpes Simplex Virus- 1, and lenti virus
- plasmid vectors encoding HO-1 or apoferritin can be administered, e.g., as naked DNA, in liposomes, or in microparticles.
- exogenous HO-1 protein can be directly administered to a patient by any method known in the art.
- Exogenous HO-1 can be directly administered in addition, or as an alternative, to the induction or expression of HO-1 in the patient as described above.
- the HO-1 protein can be delivered to a patient, for example, in liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see, e.g., Becker- Hapak et al, Methods 24:247-256, 2001).
- any of the products of metabolism by HO-1 e.g., bilirubin, biliverdin, iron, and/or ferritin
- bilirubin e.g., bilirubin, biliverdin, iron, and/or ferritin
- iron-binding molecules other than ferritin e.g., desferoxamine (DFO), iron dextran, and/or apoferritin
- enzymes e.g., biliverdin reductase
- catalyze the breakdown any of these products can be inhibited to create/enhance the desired effect.
- any of the above can be administered, e.g., orally, intravenously, intraperitoneally, or by direct administration to the inside or outside of the bowel.
- the present invention contemplates that compounds that release CO into the body after administration of the compound (e.g., CO-releasing compounds, e.g., photoactivatable CO-releasing compounds), e.g., dimanganese decacarbonyl, tricarbonyldichlororuthenium (LI) dimer, and methylene chloride (e.g., at a dose of between 400 to 600 mg/kg, e.g., about 500mg/kg), can also be used in the methods of the present invention, as can carboxyhemoglobin and CO-donating hemoglobin substitutes.
- CO-releasing compounds e.g., photoactivatable CO-releasing compounds
- methylene chloride e.g., at a dose of between 400 to 600 mg/kg, e.g., about 500mg/kg
- the above can be administered to a patient in any way, e.g., by oral, intraperitoneal, intravenous, or intraarterial administration. Any of the above compounds can be administered to the patient locally and/or systemically, and in any combination.
- the present invention further contemplates treating NEC by administering CO to the patient in combination with any other known methods or compounds for treating NEC, e.g., cessation or reduction of the rate of feeding by mouth, e.g., for at least 1 day, e.g., at least 2, 3, 5, or 10 days, or more); administering intravenous hydration and/or nutrition, nasogastric decompression, or antimicrobial agents to the patient; surgical intervention; and/or draining the patient's peritoneal cavity.
- Surgical interventions include, e.g., resecting the affected portion of the bowel.
- preventive treatment of patients at risk for NEC by administering CO to the patient in combination with any other known methods for preventing NEC, e.g., changing the patient's diet.
- Pregnant time-dated Sprague-Dawley rats were induced at term using subcutaneous injection of Pitocin (1 U). Immediately after birth (day zero), the o neonates were weighed and randomized into two main groups. Animals were either left with their mothers and thus breast-fed, or separated from their mothers, housed in an incubator (Ohio Medical Products, Madison, WI), gavage fed with a special rodent formula two times daily, and subjected to 10 minutes of hypoxia (5% O 2 , 95% N 2 ; PraxAir, Pittsburgh, PA) prior to each feeding.
- hypoxia 5% O 2 , 95% N 2 ; PraxAir, Pittsburgh, PA
- the formula consisted of 15 g 5 Similac® 60/40 (Ross Pediatrics, Colombus, OH) in 75 mL of Esbilac® canine milk replacement (Pet-Ag Inc., Hampshire, IL). Rats from each group were further randomized to receive no additional treatment or one-hour per day CO treatment (250 parts per million; ppm, days 1-3). CO was delivered as described below. The neonatal rats were sacrificed on day four. The intestines were inspected for gross necrotic 0 changes and pneumatosis intestinalis. The last 2 cm of terminal ileum was harvested for morphological studies, and mucosal scrapings were collected for detection of protein.
- H&E Hematoxylin and eosin
- Serum was collected for determination of rat TNF- ⁇ and IL-1 ⁇ levels using Quantikine® ELISA (R&D systems, Minneapolis, MN) per the manufacturer's instructions.
- the rat small-intestinal epithelial cell line IEC-6 was obtained from the American Type Culture Collection (Manassas, VA). Cells were grown in Dulbecco's modified Eagle's medium with 4.5 g/L glucose (Bio-Whittaker, Walkersville, MD) supplemented with 5% fetal bovine serum, 0.02 mM glutamine (Gibco, Grand Island, NY), 0.1 U/mL insulin, and 100 U/mL penicillin/100 ⁇ g/mL streptomycin at 37°C and 10% CO 2 . Cells from passages 3 through 20 were used for experiments.
- Cell viability was determined by measuring ATP levels (CellTiter-GloTM; Promega) as per the manufacturer's protocol.
- IEC-6 cells or ileal mucosal scrapings were collected in lysis buffer containing 20 mmol/L Tris with 100 ⁇ mol/L phenylmethylsulfonylfluoride (Sigma), 1 ⁇ mol/L leupeptin (Sigma), and 1 ⁇ mol/L sodium orthovanadate (Sigma). Protein was quantified by bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). Lysates (30 ⁇ g) were subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis.
- BCA bicinchoninic acid
- Reporter assay pGL3/2 rat iNOS promoter-luciferase reporter was constructed as described in Beck et al., FEBS Lett 435:35-38 (1998). IEC-6 cells grown in 35mm wells were transfected with 4 ⁇ L Lipofectamine2000® (Invitrogen), 0.15 ⁇ g pGL3/2 DNA and 5 0.5 ⁇ g pIEP-LacZ DNA, which was used as a control for transfection efficiency. Twenty-four hours following transfection, cells were treated for 6 hours, then lysates were collected and a luciferase assay (Promega) was performed with a luminometer (Berthold, Germany).
- Nitrite (NO 2 " ) was measured in the culture medium using the Griess method.
- Results are expressed as mean ⁇ SEM. Differences among groups were 5 analyzed with one-way analysis of variance with Student-Newman-Keuls post-hoc test for all pairwise comparisons (SigmaStat; SPSS, Chicago, LL). Statistical significance was assumed when P was less than 0.05.
- Intestinal HO-1 protein is increased in NEC 0
- Human intestinal specimens from patients with NEC and control intestinal specimens from patients with non-inflammatory conditions were analyzed for expression of HO-1.
- Whole cell lysates from NEC specimens demonstrated increased expression of HO-1 compared to controls (Fig. 1A).
- Neonatal rats from breast fed and H/F groups were randomized to receive either one-hour doses of CO (250 ppm) per day on days 1, 2, and 3, or no additional therapy. All animals were sacrificed on day 4 of life. Gross pathological characteristics including pneumatosis intestinalis and necrosis (see Table 1, below) as well as histological changes consistent with experimental NEC were identified in the H F group compared to breast fed controls (Fig. 2A, 2B, 2C, and 2D). CO treatment had no effect on gross or microscopic evaluation of breast fed animals and significantly protected against the development of experimental NEC in rats in the H/F group. TUNEL staining for cell death, which was increased in the H/F group, was diminished by CO treatment (Fig. 3A, 3B, 3C, and 3D).
- LL-l ⁇ levels as systemic markers of tissue inflammation.
- Levels of both TNF- ⁇ and IL-l ⁇ were increased by 33.2 and 18.5 fold in the H/F group compared to breast fed controls (Figs. 4A and 4B; P ⁇ 0.05). CO significantly attenuated these increases, resulting in only 3 and 2.5 fold increases in TNF- ⁇ and LL-l ⁇ , respectively (P ⁇ 0.05).
- CO inhibits generation of intestinal inducible nitric oxide synthase (iNOS) iNOS is increased in human intestinal specimens from neonates with NEC as well as in the intestines of rats in experimental models of NEC. Induction of iNOS and NO generation are believed to contribute directly to tissue damage via formation of
- the rat intestinal epithelial cell line IEC-6 was utilized.
- Cell death was induced by treating these cells 5 with TNF- ⁇ (10 ng/ml) plus actinomycin D (ActD; 200 ng/ml).
- TNF- ⁇ / ActD decreased IEC-6 cell viability to 24 ⁇ 2.1% that of untreated controls (Fig. 7; P ⁇ 0.05).
- CO 0 alone had no measurable effect on viability of IEC-6 cells in vitro.
- Induction of HO-1 by CoPP had similar protective effects.
- CO limited this transcriptional activation to only a 1.7 ⁇ 0.2 fold increase(P ⁇ 0.05). Additionally, the effect of CO on NO generation by IEC-6 cells was assayed by measuring nitrite. IEC-6 cells were stimulated with a cytokine mixture (TNF- ⁇ , LL-l ⁇ , Interferon- ⁇ ) that is known to upregulate iNOS. Cytokine stimulation increased iNOS protein (Fig. 8C) as well as nitrite to 17.2 ⁇ 0.9 ⁇ M compared to 1.4+0.3 ⁇ M in unstimulated controls (P ⁇ 0.01; Fig. 8D). CO and CoPP significantly inhibited this cytokine effect resulting in nitrite levels of 9.8 + 0.7 and 10.4 + 1.0, respectively (P ⁇ 0.05).
- a cytokine mixture TNF- ⁇ , LL-l ⁇ , Interferon- ⁇
- Cytokine stimulation increased iNOS protein (Fig. 8C) as well as nitrite to 17.2 ⁇ 0.9
- HO-1 is upregulated in intestinal specimens from human neonates with NEC as well as in the ileal mucosa of neonatal rats in a model of experimental NEC.
- One-hour per day of exogenous CO delivery prevented the development of NEC. This was associated with a decrease in systemic inflammation as assayed by serum TNF- ⁇ and LL-l ⁇ , and local inflammation as assayed by ileal mucosal expression of IL-l ⁇ and COX-2.
- the development of NEC was also associated with increased ileal mucosal iNOS expression and protein nitration.
- CO therapy attenuated the increase in iNOS and nitrosative stress.
- induction of HO-1 or CO is protective against TNF- ⁇ / ActD-induced cell death in IEC-6 cells. Additionally in vitro, CO prevented iNOS induction and NO generation.
- HO-1 and its catalytic by-products, including CO likely play a defensive role following intestinal injury.
- the data presented above demonstrate that levels of HO-1 protein are increased in the ileal mucosa of animals with NEC, which is consistent with previous studies demonstrating increased intestinal HO-1 in models of ischemia/reperfusion and hemorrhagic shock.
- Induction of HO-1, by pre-conditioning or pharmacologically, is cytoprotective following intestinal transplantation and ischemia/reperfusion.
- CO treatment which is protective against the development of NEC, also prevented the upregulation of HO-1. This inhibition of HO-1 expression may be due to a direct negative feedback loop; however, this is likely secondary to the protection against intestinal injury with subsequent upregulation of HO-1.
- the following example illustrates protocols for use in treating a patient suffering from or at risk for NEC.
- the example also illustrates protocols for treating patients before, during, and/or after surgical procedures, e.g., a surgical procedure to treat NEC, e.g., a surgery in which a portion of the bowel is resected.
- a surgical procedure to treat NEC e.g., a surgery in which a portion of the bowel is resected.
- Skilled 5 practitioners will appreciate that any protocol described herein can be adapted based on a patient's individual needs, and can be adapted to be used in conjunction with any other treatment for NEC.
- Treatment of a patient with CO can begin on the day the patient is diagnosed as suffering from NEC or any condition associated with NEC, or as having any risk factor 0 associated with an increased likelihood that the patient will develop NEC.
- Patients can inhale CO at concentrations ranging from 10 ppm to 1000 ppm, e.g., about 100 ppm to about 800 ppm, about 150 ppm to about 600 ppm, or about 200 ppm to about 500 ppm.
- Preferred concentrations include, e.g., about 30 ppm, 50 ppm, 75 ppm, 100 ppm, 125 ppm, 200 ppm, 250 ppm, 500 ppm, 750 ppm, or about 1000 ppm.
- CO can be administered to the patient intermittently or continuously.
- CO can be administered for about 1, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, or greater than 20 days, e.g., 1 2, 3, 5, or 6 months, or until the patient no longer exhibits symptoms of NEC, or until the patient is diagnosed as no longer being at risk for NEC.
- CO can be administered continuously for the entire day, or intermittently, e.g., a single whiff of CO per day (where a high concentration is used), or for up to 23 hours per day, e.g., up to 20, 15, 12, 10, 6, 3, or 2 hours per day, or up to 1 hour per day.
- CO can be administered systemically or locally to a patient prior to, during, and/or after a surgical procedure is performed.
- Patients can inhale CO at concentrations ranging from 10 ppm to 1000 ppm, e.g., about 100 ppm to about 800 ppm, about 150 ppm to about 600 ppm, or about 200 ppm to about 500 ppm.
- concentrations include, e.g., about 30 ppm, 50 ppm, 75 ppm, 100 ppm, 125 ppm, 200 ppm, 250 ppm, 500 ppm, 750 ppm, or about 1000 ppm.
- CO can be administered to the patient intermittently or continuously, for about 1, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, or greater than 20 days, before the procedure.
- CO can be administered to the patient during the procedure, e.g., by inhalation and/or topical administration.
- CO can be administered to the patient after the procedure, e.g., starting immediately after completion of the procedure, and continuing for about 1, 2, 3, 5, 7, or 10 hours, or about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, indefinitely, or until the patient no longer suffers from, or is at risk for, NEC after the completion of the procedure.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03719698.7A EP1499328B1 (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis |
MXPA04010242A MXPA04010242A (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis. |
CA002481786A CA2481786A1 (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis |
JP2003585733A JP4585765B2 (en) | 2002-04-15 | 2003-04-15 | How to treat necrotizing enterocolitis |
EA200401366A EA200401366A1 (en) | 2002-04-15 | 2003-04-15 | METHODS OF TREATMENT OF NONCROTIZING ENTEROKOLITIS |
YUP-911/04A RS91104A (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis |
ES03719698.7T ES2554108T3 (en) | 2002-04-15 | 2003-04-15 | Methods of treatment of necrotizing enterocolitis |
AU2003223562A AU2003223562B2 (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis |
HR20040973A HRP20040973A2 (en) | 2002-04-15 | 2004-10-15 | Method of treating necrotizing enterocolitis |
NO20044564A NO20044564L (en) | 2002-04-15 | 2004-10-22 | Methods for treating necrotizing enterocolitis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37259902P | 2002-04-15 | 2002-04-15 | |
US60/372,599 | 2002-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003088981A1 true WO2003088981A1 (en) | 2003-10-30 |
Family
ID=29250879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/011167 WO2003088981A1 (en) | 2002-04-15 | 2003-04-15 | Methods of treating necrotizing enterocolitis |
Country Status (15)
Country | Link |
---|---|
US (1) | US7981448B2 (en) |
EP (1) | EP1499328B1 (en) |
JP (1) | JP4585765B2 (en) |
CN (1) | CN1652802A (en) |
AU (1) | AU2003223562B2 (en) |
CA (1) | CA2481786A1 (en) |
EA (1) | EA200401366A1 (en) |
ES (1) | ES2554108T3 (en) |
HR (1) | HRP20040973A2 (en) |
MX (1) | MXPA04010242A (en) |
NO (1) | NO20044564L (en) |
PL (1) | PL374241A1 (en) |
RS (1) | RS91104A (en) |
UA (1) | UA86570C2 (en) |
WO (1) | WO2003088981A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045140B2 (en) | 2001-05-15 | 2006-05-16 | Hemocorm Limited | Therapeutic delivery of carbon monoxide |
EP2151242A1 (en) * | 2008-08-06 | 2010-02-10 | Nowak, Götz | Use of oxygen for treatment of illnesses of the mucous membrane of the intestinal channel |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7687079B2 (en) | 2002-04-15 | 2010-03-30 | University of Pittsburgh of the Commonwealth System of Higher Education Yale University | Methods of treating ileus |
US7981448B2 (en) | 2002-04-15 | 2011-07-19 | University Of Pittsburgh | Methods of treating necrotizing enterocolitis |
US7993681B2 (en) | 2003-10-22 | 2011-08-09 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in tissues and organs |
US9023402B2 (en) | 2002-02-04 | 2015-05-05 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for treating a mammal by administration of a compound having the ability to release CO |
US9062089B2 (en) | 2011-07-21 | 2015-06-23 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
US9163044B2 (en) | 2011-04-19 | 2015-10-20 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
US9987302B2 (en) | 2011-08-09 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating DNA damage |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60229848D1 (en) * | 2001-06-21 | 2008-12-24 | Beth Israel Hospital | - AND ORGANTRANSPLANTATIONS AND SUPPRESSING APOPTOSIS |
WO2003088748A1 (en) | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
UA87438C2 (en) * | 2002-06-05 | 2009-07-27 | Йельский Университет | Method for treatment or prophylaxis of cancer, method for performing of surgical operation for cancer ablation and us of carbon monooxide |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
AU2003283982A1 (en) * | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
WO2007073006A1 (en) * | 2005-12-22 | 2007-06-28 | Keio University | Inducer for increasing of content of cytoprotective amino acid and method for increasing the content |
DK3498328T3 (en) | 2009-05-27 | 2021-01-18 | Mallinckrodt Hospital Products Ip Ltd | DEVICE FOR CONNECTION OF INDEXED VALVE AND PRESSURE CONTAINER ASSEMBLY WITH REQUIREMENTS AND FOR LINEAR ACTIVATION WITH PISTON COLLECTION IN FLUID CONNECTION WITH DEVICE FOR REGULATION OF MEDICINE DELIVERY |
CA2671029A1 (en) | 2009-06-30 | 2010-12-30 | James S. Baldassarre | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
EP2663193B1 (en) | 2011-01-14 | 2019-05-08 | Children's Hospital Los Angeles | Solution of carbon monoxide for treatment of disease, including sickle cell disease |
CN103263715B (en) * | 2013-05-24 | 2015-12-02 | 史源 | Carbon monoxide sucks instrument |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
TW201618795A (en) | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | Systems and methods to improve organ function and organ transplant longevity |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5679957A (en) * | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US5792325A (en) * | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4264739A (en) * | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
US5240912A (en) * | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US5084380A (en) * | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) * | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
DE3739650C1 (en) * | 1987-11-23 | 1989-05-24 | Immuno Ag | Fermenter for growing cell cultures |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
DE69433723T3 (en) * | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
EP0804244A1 (en) | 1993-03-26 | 1997-11-05 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5763431A (en) * | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
DE4421433C1 (en) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for treatment of, e.g., hypertension |
US5476764A (en) * | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5664563A (en) * | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) * | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735382B1 (en) * | 1995-06-15 | 1997-07-25 | Air Liquide | CARBON MONOXIDE PRODUCTION PLANT INCORPORATING A CRYOGENIC SEPARATION UNIT |
AU5938696A (en) * | 1995-06-30 | 1997-02-05 | Zymogenetics Inc. | 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists |
ES2267141T3 (en) * | 1996-04-05 | 2007-03-01 | The General Hospital Corporation | TREATMENT OF A HEMOGLOBINOPATIA. |
US6069132A (en) * | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
PT921807E (en) | 1996-08-27 | 2004-04-30 | Messer Griesheim Gmbh | MEDICINES CONTAINING HYDROGEN |
ATE358492T1 (en) | 1996-09-27 | 2007-04-15 | Univ Columbia | TREATMENT OF ISCHEMIC DISORDER AND TO IMPROVE INFARCT OUTCOME |
US6316403B1 (en) * | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US6315995B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
NZ506432A (en) | 1998-03-16 | 2003-08-29 | Celgene Corp | 2-(2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6203991B1 (en) * | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US20050250688A1 (en) * | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7632803B2 (en) * | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
FR2812197B1 (en) | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | USE OF CO IN THE TREATMENT OF INFLAMMATION OF THE UPPER AIRWAYS OR BRONCHIA |
FR2816212A1 (en) | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation |
US20040197271A1 (en) * | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
CN1507348A (en) | 2001-03-30 | 2004-06-23 | ɣ����ҽҩ��˾ | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
WO2002096387A1 (en) | 2001-05-25 | 2002-12-05 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
DE60229848D1 (en) * | 2001-06-21 | 2008-12-24 | Beth Israel Hospital | - AND ORGANTRANSPLANTATIONS AND SUPPRESSING APOPTOSIS |
WO2003066067A2 (en) | 2002-02-04 | 2003-08-14 | Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
SG148850A1 (en) * | 2002-02-13 | 2009-01-29 | Beth Israel Hospital | Methods of treating vascular disease |
CA2481786A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
WO2003088748A1 (en) * | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
EP1499333B1 (en) | 2002-04-15 | 2015-06-24 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Carbon monoxide for use in a method of treating ileus |
AU2002308676B2 (en) | 2002-05-09 | 2009-06-11 | Johns Hopkins University | Carbon monoxide as a biomarker and therapeutic agent |
MXPA04011426A (en) * | 2002-05-17 | 2005-10-19 | Univ Yale | Methods of treating hepatitis. |
UA87438C2 (en) | 2002-06-05 | 2009-07-27 | Йельский Университет | Method for treatment or prophylaxis of cancer, method for performing of surgical operation for cancer ablation and us of carbon monooxide |
US20040131703A1 (en) | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
DE10230165A1 (en) | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Method and device for the administration of carbon monoxide |
AU2003283982A1 (en) | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
-
2003
- 2003-04-15 CA CA002481786A patent/CA2481786A1/en not_active Abandoned
- 2003-04-15 UA UA20041109278A patent/UA86570C2/en unknown
- 2003-04-15 RS YUP-911/04A patent/RS91104A/en unknown
- 2003-04-15 MX MXPA04010242A patent/MXPA04010242A/en active IP Right Grant
- 2003-04-15 EP EP03719698.7A patent/EP1499328B1/en not_active Expired - Lifetime
- 2003-04-15 US US10/413,817 patent/US7981448B2/en not_active Expired - Fee Related
- 2003-04-15 WO PCT/US2003/011167 patent/WO2003088981A1/en active Application Filing
- 2003-04-15 AU AU2003223562A patent/AU2003223562B2/en not_active Ceased
- 2003-04-15 CN CNA038113104A patent/CN1652802A/en active Pending
- 2003-04-15 PL PL03374241A patent/PL374241A1/en unknown
- 2003-04-15 JP JP2003585733A patent/JP4585765B2/en not_active Expired - Fee Related
- 2003-04-15 EA EA200401366A patent/EA200401366A1/en unknown
- 2003-04-15 ES ES03719698.7T patent/ES2554108T3/en not_active Expired - Lifetime
-
2004
- 2004-10-15 HR HR20040973A patent/HRP20040973A2/en not_active Application Discontinuation
- 2004-10-22 NO NO20044564A patent/NO20044564L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5679957A (en) * | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US5792325A (en) * | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Derwent World Patents Index; AN 1981-59741D, XP002968178, "Yersinia entercolitica polysaccharide-sensitised blood corpussles" * |
See also references of EP1499328A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7045140B2 (en) | 2001-05-15 | 2006-05-16 | Hemocorm Limited | Therapeutic delivery of carbon monoxide |
US9023402B2 (en) | 2002-02-04 | 2015-05-05 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for treating a mammal by administration of a compound having the ability to release CO |
US7687079B2 (en) | 2002-04-15 | 2010-03-30 | University of Pittsburgh of the Commonwealth System of Higher Education Yale University | Methods of treating ileus |
US7981448B2 (en) | 2002-04-15 | 2011-07-19 | University Of Pittsburgh | Methods of treating necrotizing enterocolitis |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
US7993681B2 (en) | 2003-10-22 | 2011-08-09 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in tissues and organs |
EP2151242A1 (en) * | 2008-08-06 | 2010-02-10 | Nowak, Götz | Use of oxygen for treatment of illnesses of the mucous membrane of the intestinal channel |
US9163044B2 (en) | 2011-04-19 | 2015-10-20 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
US9062089B2 (en) | 2011-07-21 | 2015-06-23 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
US9611286B2 (en) | 2011-07-21 | 2017-04-04 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
US9987302B2 (en) | 2011-08-09 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating DNA damage |
Also Published As
Publication number | Publication date |
---|---|
EP1499328A1 (en) | 2005-01-26 |
RS91104A (en) | 2007-02-05 |
AU2003223562A1 (en) | 2003-11-03 |
JP4585765B2 (en) | 2010-11-24 |
US7981448B2 (en) | 2011-07-19 |
US20040005367A1 (en) | 2004-01-08 |
EP1499328A4 (en) | 2008-03-26 |
CA2481786A1 (en) | 2003-10-30 |
CN1652802A (en) | 2005-08-10 |
AU2003223562B2 (en) | 2009-04-09 |
EA200401366A1 (en) | 2006-02-24 |
MXPA04010242A (en) | 2005-06-08 |
HRP20040973A2 (en) | 2005-06-30 |
UA86570C2 (en) | 2009-05-12 |
EP1499328B1 (en) | 2015-09-16 |
JP2005530737A (en) | 2005-10-13 |
PL374241A1 (en) | 2005-10-03 |
NO20044564L (en) | 2004-11-18 |
ES2554108T3 (en) | 2015-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7981448B2 (en) | Methods of treating necrotizing enterocolitis | |
US20040228930A1 (en) | Treatment for hemorrhagic shock | |
ES2372273T3 (en) | METHODS OF TREATMENT OF HEPATITIS. | |
ES2546280T3 (en) | Carbon monoxide for use in a method to treat ileus | |
US20040258772A1 (en) | Methods of treating angiogenesis, tumor growth, and metastasis | |
JP2005533812A (en) | Pharmaceutical use of nitric oxide, heme oxygenase-1 and heme degradation products | |
AU2002308676A1 (en) | Carbon monoxide as a biomarker and therapeutic agent | |
US8778413B2 (en) | Dosing regimens and methods of treatment using carbon monoxide | |
Himashree et al. | Nitric oxide and the respiratory system | |
AU2003234585B2 (en) | Methods of treating hepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-911/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003223562 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2481786 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20040973A Country of ref document: HR Ref document number: 2003585733 Country of ref document: JP Ref document number: 374241 Country of ref document: PL Ref document number: PA/a/2004/010242 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3548/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003719698 Country of ref document: EP Ref document number: 200401366 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038113104 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003719698 Country of ref document: EP |